BofA initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $31 price target Caris is a molecular diagnostic company with a “differentiated, data-driven platform” for tissue-based tumor profiling, the analyst tells investors in a research note. The firm believes the company stands out due to its breadth of tests, artificial intelligence analysis, and high reimbursement rate. BofA believes Caris has a market leading financial profile and deserves a multiple above peers.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences initiated with a Buy at Guggenheim
- Caris Life Sciences: Strong Market Position and Growth Potential Justify Buy Rating
- Caris Life Sciences publishes Assure liquid biopsy platform study
- Caris Life Sciences vice chairman Brille buys 30,000 common shares
- Opening Day: Caris jumps as investors buy into ‘AI TechBio company’